Geo Capital Gestora de Recursos Ltd Purchases 43,678 Shares of Novo Nordisk A/S (NYSE:NVO)

Geo Capital Gestora de Recursos Ltd increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 157.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 71,341 shares of the company's stock after acquiring an additional 43,678 shares during the period. Novo Nordisk A/S makes up about 7.9% of Geo Capital Gestora de Recursos Ltd's portfolio, making the stock its 3rd largest holding. Geo Capital Gestora de Recursos Ltd's holdings in Novo Nordisk A/S were worth $6,137,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S during the third quarter valued at $28,000. Center for Financial Planning Inc. lifted its stake in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares in the last quarter. Dunhill Financial LLC boosted its holdings in Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company's stock worth $56,000 after buying an additional 311 shares during the last quarter. Albion Financial Group UT increased its stake in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after buying an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $46,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Remove Ads

Novo Nordisk A/S Trading Down 2.5 %

Shares of NVO stock traded down $1.86 during trading on Wednesday, hitting $71.74. 7,578,994 shares of the stock traded hands, compared to its average volume of 5,461,055. Novo Nordisk A/S has a 52-week low of $71.62 and a 52-week high of $148.15. The firm has a market capitalization of $321.94 billion, a P/E ratio of 21.81, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The firm's fifty day moving average price is $83.01 and its 200-day moving average price is $99.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's payout ratio is 47.72%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVO. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Friday, March 21st. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.